These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 14736254)

  • 1. Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues.
    Tömböly C; Kövér KE; Péter A; Tourwé D; Biyashev D; Benyhe S; Borsodi A; Al-Khrasani M; Rónai AZ; Tóth G
    J Med Chem; 2004 Jan; 47(3):735-43. PubMed ID: 14736254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
    Bonner GG; Davis P; Stropova D; Edsall S; Yamamura HI; Porreca F; Hruby VJ
    J Med Chem; 2000 Feb; 43(4):569-80. PubMed ID: 10691683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, pharmacological evaluation, and structure-activity study of novel endomorphin analogues with multiple structural modifications.
    Mallareddy JR; Borics A; Keresztes A; Kövér KE; Tourwé D; Tóth G
    J Med Chem; 2011 Mar; 54(5):1462-72. PubMed ID: 21287991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Pro(2) modifications on the structural and pharmacological properties of endomorphin-2.
    Borics A; Mallareddy JR; Timári I; Kövér KE; Keresztes A; Tóth G
    J Med Chem; 2012 Oct; 55(19):8418-28. PubMed ID: 22957923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity study on the spatial arrangement of the third aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus.
    Yu Y; Shao X; Cui Y; Liu HM; Wang CL; Fan YZ; Liu J; Dong SL; Cui YX; Wang R
    ChemMedChem; 2007 Mar; 2(3):309-17. PubMed ID: 17285661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
    Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
    J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
    Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
    Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endomorphin-1 analogues containing beta-proline are mu-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance.
    Cardillo G; Gentilucci L; Qasem AR; Sgarzi F; Spampinato S
    J Med Chem; 2002 Jun; 45(12):2571-8. PubMed ID: 12036366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
    Li T; Fujita Y; Tsuda Y; Miyazaki A; Ambo A; Sasaki Y; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2005 Jan; 48(2):586-92. PubMed ID: 15658871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endomorphin 1[psi] and endomorphin 2[psi], endomorphins analogues containing a reduced (CH2NH) amide bond between Tyr1 and Pro2, display partial agonist potency but significant antinociception.
    Zhao QY; Chen Q; Yang DJ; Feng Y; Long Y; Wang P; Wang R
    Life Sci; 2005 Jul; 77(10):1155-65. PubMed ID: 15878600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
    Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
    Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly potent side chain-main chain cyclized dermorphin-deltorphin analogues: an integrated approach including synthesis, bioassays, NMR spectroscopy and molecular modelling.
    Ro S; Zhu Q; Lee CW; Goodman M; Darlak K; Spatola AF; Chung NN; Schiller PW; Malmberg AB; Yaksh TL
    J Pept Sci; 1995; 1(3):157-74. PubMed ID: 9222993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro binding and signaling profile of the novel mu opioid receptor agonist endomorphin 2 in rat brain membranes.
    Spetea M; Monory K; Tömböly C; Tóth G; Tzavara E; Benyhe S; Hanoune J; Borsodi A
    Biochem Biophys Res Commun; 1998 Sep; 250(3):720-5. PubMed ID: 9784412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties.
    Tömböly C; Ballet S; Feytens D; Kövér KE; Borics A; Lovas S; Al-Khrasani M; Fürst Z; Tóth G; Benyhe S; Tourwé D
    J Med Chem; 2008 Jan; 51(1):173-7. PubMed ID: 18062664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endomorphins--endogenous ligands of the mu-opioid receptor].
    Perlikowska R; Fichna J; Janecka A
    Postepy Biochem; 2009; 55(4):388-94. PubMed ID: 20201352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
    Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of novel peptide inhibitors of endomorphin-degrading enzymes in the rat brain.
    Fichna J; Janecka A; Bailly L; Marsais F; Costentin J; do Rego JC
    Chem Biol Drug Des; 2006 Sep; 68(3):173-5. PubMed ID: 17062015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1.
    Paterlini MG; Avitabile F; Ostrowski BG; Ferguson DM; Portoghese PS
    Biophys J; 2000 Feb; 78(2):590-9. PubMed ID: 10653774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.